Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 802

1.

Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.

Fanotto V, Fornaro L, Bordonaro R, Rosati G, Rimassa L, Di Donato S, Santini D, Tomasello G, Leone F, Silvestris N, Stragliotto S, Scartozzi M, Giampieri R, Nichetti F, Antonuzzo L, Cinieri S, Avallone A, Pellegrino A, Melisi D, Vasile E, Gerratana L, Aprile G.

J Geriatr Oncol. 2018 Dec 11. pii: S1879-4068(18)30300-X. doi: 10.1016/j.jgo.2018.11.009. [Epub ahead of print]

PMID:
30551958
2.

MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk.

Modica C, Tortarolo D, Comoglio PM, Basilico C, Vigna E.

Int J Mol Sci. 2018 Dec 7;19(12). pii: E3920. doi: 10.3390/ijms19123920. Review.

PMID:
30544501
3.

Functional fat injection under local anesthesia to treat severe postsurgical dysphagia, a case report.

Ottaviani F, Schindler A, Klinger F, Scarponi L, Succo G, Mozzanica F.

Head Neck. 2018 Dec 11. doi: 10.1002/hed.25465. [Epub ahead of print]

PMID:
30536961
4.

Early-onset colorectal cancer in young individuals.

Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S.

Mol Oncol. 2018 Dec 6. doi: 10.1002/1878-0261.12417. [Epub ahead of print] Review.

5.

Irreversible activation of Rho-activated kinases resulted from evolution of proteolytic sites within disordered regions in coiled-coil domain.

Armando Gagliardi P, Primo L.

Mol Biol Evol. 2018 Dec 4. doi: 10.1093/molbev/msy229. [Epub ahead of print]

PMID:
30517755
6.

RollFISH achieves robust quantification of single-molecule RNA biomarkers in paraffin-embedded tumor tissue samples.

Wu C, Simonetti M, Rossell C, Mignardi M, Mirzazadeh R, Annaratone L, Marchiò C, Sapino A, Bienko M, Crosetto N, Nilsson M.

Commun Biol. 2018 Nov 28;1:209. doi: 10.1038/s42003-018-0218-0. eCollection 2018.

7.

Inactivation of DNA repair-prospects for boosting cancer immune surveillance.

Truini A, Germano G, Bardelli A.

Genome Med. 2018 Nov 28;10(1):91. doi: 10.1186/s13073-018-0603-9.

8.

Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease: A Review.

Chohan MO, Marchiò S, Morrison LA, Sidman RL, Cavenee WK, Dejana E, Yonas H, Pasqualini R, Arap W.

JAMA Neurol. 2018 Nov 26. doi: 10.1001/jamaneurol.2018.3634. [Epub ahead of print]

PMID:
30476961
9.

Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer.

Siravegna G, Bardelli A.

Ann Oncol. 2018 Nov 26. doi: 10.1093/annonc/mdy525. [Epub ahead of print] No abstract available.

PMID:
30475974
10.

The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers.

Germano G, Amirouchene-Angelozzi N, Rospo G, Bardelli A.

Cancer Discov. 2018 Dec;8(12):1518-1528. doi: 10.1158/2159-8290.CD-18-0150. Epub 2018 Nov 15. Review.

PMID:
30442708
11.

Radiomics and liquid biopsy in oncology: the holons of systems medicine.

Neri E, Del Re M, Paiar F, Erba P, Cocuzza P, Regge D, Danesi R.

Insights Imaging. 2018 Dec;9(6):915-924. doi: 10.1007/s13244-018-0657-7. Epub 2018 Nov 14. Review.

12.

Deep Learning Electronic Cleansing for Single- and Dual-Energy CT Colonography.

Tachibana R, Näppi JJ, Ota J, Kohlhase N, Hironaka T, Kim SH, Regge D, Yoshida H.

Radiographics. 2018 Nov-Dec;38(7):2034-2050. doi: 10.1148/rg.2018170173.

PMID:
30422761
13.

What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?

Giannone G, Milani A, Geuna E, Galizia D, Biello F, Montemurro F.

Expert Opin Pharmacother. 2018 Nov 6:1-5. doi: 10.1080/14656566.2018.1543406. [Epub ahead of print] No abstract available.

PMID:
30396301
14.

Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.

Zambetti M, Montemurro F, Morandi P, Zamagni C, Brandes AA, Bisagni G, Cagossi K, Bengala C, Gori S, Iannacone C, Stell A, Gianni L.

Eur J Cancer. 2018 Dec;105:61-70. doi: 10.1016/j.ejca.2018.09.034. Epub 2018 Nov 3.

PMID:
30396014
15.

Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.

Mesiano G, Grignani G, Fiorino E, Leuci V, Rotolo R, D'Ambrosio L, Salfi C, Gammaitoni L, Giraudo L, Pisacane A, Butera S, Pignochino Y, Basiricó M, Capozzi F, Sapino A, Aglietta M, Sangiolo D.

Oncoimmunology. 2018 Aug 6;7(11):e1465161. doi: 10.1080/2162402X.2018.1465161. eCollection 2018.

16.

Reproducible bioinformatics project: a community for reproducible bioinformatics analysis pipelines.

Kulkarni N, Alessandrì L, Panero R, Arigoni M, Olivero M, Ferrero G, Cordero F, Beccuti M, Calogero RA.

BMC Bioinformatics. 2018 Oct 15;19(Suppl 10):349. doi: 10.1186/s12859-018-2296-x.

17.

Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue.

Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA.

Ann Oncol. 2018 Oct 11. doi: 10.1093/annonc/mdy450. [Epub ahead of print]

PMID:
30307529
18.

Correction to: Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity.

Castiglia S, Adamini A, Rustichelli D, Castello L, Mareschi K, Pinnetta G, Leone M, Mandese A, Ferrero I, Mesiano G, Fagioli F.

J Transl Med. 2018 Oct 10;16(1):275. doi: 10.1186/s12967-018-1656-7.

19.

Deficiencies in health-related quality of life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.

Marandino L, La Salvia A, Sonetto C, De Luca E, Pignataro D, Zichi C, Di Stefano RF, Ghisoni E, Lombardi P, Mariniello A, Reale ML, Trevisi E, Leone G, Muratori L, Marcato M, Bironzo P, Novello S, Aglietta M, Scagliotti GV, Perrone F, Di Maio M.

Ann Oncol. 2018 Oct 10. doi: 10.1093/annonc/mdy449. [Epub ahead of print]

PMID:
30304498
20.

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).

Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, Moriarty A, Cutler RE Jr, Avogadri-Connors F, Lalani AS, Bryce RP, Chandarlapaty S, Hyman DM, Solit DB, Boni V, Loi S, Baselga J, Berger MF, Montemurro F, Scaltriti M.

Sci Signal. 2018 Oct 9;11(551). pii: eaat9773. doi: 10.1126/scisignal.aat9773.

PMID:
30301790

Supplemental Content

Loading ...
Support Center